These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

73 related articles for article (PubMed ID: 2905893)

  • 21. Differential interaction of competitive NMDA and AMPA antagonists with selective dopamine D-1 and D-2 agonists in a rat model of Parkinson's disease.
    Löschmann PA; Wüllner U; Heneka MT; Schulz JB; Kunow M; Wachtel H; Klockgether T
    Synapse; 1997 Aug; 26(4):381-91. PubMed ID: 9215597
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Depressive-like behaviors alterations induced by intranigral MPTP, 6-OHDA, LPS and rotenone models of Parkinson's disease are predominantly associated with serotonin and dopamine.
    Santiago RM; Barbieiro J; Lima MM; Dombrowski PA; Andreatini R; Vital MA
    Prog Neuropsychopharmacol Biol Psychiatry; 2010 Aug; 34(6):1104-14. PubMed ID: 20547199
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Experimental models, of Parkinson disease].
    Luquin MR
    Rev Neurol; 2000 Jul 1-15; 31(1):60-6. PubMed ID: 10948587
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Nasogastric and intravenous infusions of (+)-4-propyl-9-hydroxynaphthoxazine (PHNO) in Parkinson's disease.
    Coleman RJ; Quinn NP; Traub M; Marsden CD
    J Neurol Neurosurg Psychiatry; 1990 Feb; 53(2):102-5. PubMed ID: 1968963
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Antiparkinsonian action of a delta opioid agonist in rodent and primate models of Parkinson's disease.
    Hille CJ; Fox SH; Maneuf YP; Crossman AR; Brotchie JM
    Exp Neurol; 2001 Nov; 172(1):189-98. PubMed ID: 11681851
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Recent progress in development of psychotropic drugs (3)--Antiparkinsonian agents applied in the treatment of Parkinson's disease or are under investigation for patients or model animals].
    Nomoto M
    Nihon Shinkei Seishin Yakurigaku Zasshi; 1996 Aug; 16(4):113-22. PubMed ID: 8905800
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Changes of D1 and D2 dopamine receptor mRNA in the brains of monkeys lesioned with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine: correction with chronic administration of L-3,4-dihydroxyphenylalanine.
    Morissette M; Goulet M; Calon F; Falardeau P; Blanchet PJ; Bédard PJ; Di Paolo T
    Mol Pharmacol; 1996 Nov; 50(5):1073-9. PubMed ID: 8913337
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Asymptomatic striatal dopamine depletion: PET scans in unilateral MPTP monkeys.
    Guttman M; Yong VW; Kim SU; Calne DB; Martin WR; Adam MJ; Ruth TJ
    Synapse; 1988; 2(5):469-73. PubMed ID: 3263709
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effect of repeated L-DOPA, bromocriptine, or lisuride administration on preproenkephalin-A and preproenkephalin-B mRNA levels in the striatum of the 6-hydroxydopamine-lesioned rat.
    Henry B; Crossman AR; Brotchie JM
    Exp Neurol; 1999 Feb; 155(2):204-20. PubMed ID: 10072296
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Combined 5-HT1A and 5-HT1B receptor agonists for the treatment of L-DOPA-induced dyskinesia.
    Muñoz A; Li Q; Gardoni F; Marcello E; Qin C; Carlsson T; Kirik D; Di Luca M; Björklund A; Bezard E; Carta M
    Brain; 2008 Dec; 131(Pt 12):3380-94. PubMed ID: 18952677
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Swim-test as a function of motor impairment in MPTP model of Parkinson's disease: a comparative study in two mouse strains.
    Haobam R; Sindhu KM; Chandra G; Mohanakumar KP
    Behav Brain Res; 2005 Sep; 163(2):159-67. PubMed ID: 15941598
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Social enrichment attenuates nigrostriatal lesioning and reverses motor impairment in a progressive 1-methyl-2-phenyl-1,2,3,6-tetrahydropyridine (MPTP) mouse model of Parkinson's disease.
    Goldberg NR; Fields V; Pflibsen L; Salvatore MF; Meshul CK
    Neurobiol Dis; 2012 Mar; 45(3):1051-67. PubMed ID: 22198503
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Neuroprotective effects of stemazole in the MPTP-induced acute model of Parkinson's disease: Involvement of the dopamine system.
    Guo Z; Xu S; Du N; Liu J; Huang Y; Han M
    Neurosci Lett; 2016 Mar; 616():152-9. PubMed ID: 26827716
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Synergism of NBQX with dopamine agonists in the 6-OHDA rat model of Parkinson's disease.
    Löschmann PA; Kunow M; Wachtel H
    J Neural Transm Suppl; 1992; 38():55-64. PubMed ID: 1491248
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Continuous dopaminergic stimulation by pramipexole is effective to treat early morning akinesia in animal models of Parkinson's disease: A pharmacokinetic-pharmacodynamic study using in vivo microdialysis in rats.
    Ferger B; Buck K; Shimasaki M; Koros E; Voehringer P; Buerger E
    Synapse; 2010 Jul; 64(7):533-41. PubMed ID: 20196139
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Behavioral recovery in a primate model of Parkinson's disease by triple transduction of striatal cells with adeno-associated viral vectors expressing dopamine-synthesizing enzymes.
    Muramatsu S; Fujimoto K; Ikeguchi K; Shizuma N; Kawasaki K; Ono F; Shen Y; Wang L; Mizukami H; Kume A; Matsumura M; Nagatsu I; Urano F; Ichinose H; Nagatsu T; Terao K; Nakano I; Ozawa K
    Hum Gene Ther; 2002 Feb; 13(3):345-54. PubMed ID: 11860702
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Dopamine receptors: effects of chronic L-dopa and bromocriptine treatment in an animal model of Parkinson's disease.
    Schneider MB; Murrin LC; Pfeiffer RF; Deupree JD
    Clin Neuropharmacol; 1984; 7(3):247-57. PubMed ID: 6435870
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Noradrenaline neuron degeneration contributes to motor impairments and development of L-DOPA-induced dyskinesia in a rat model of Parkinson's disease.
    Shin E; Rogers JT; Devoto P; Björklund A; Carta M
    Exp Neurol; 2014 Jul; 257():25-38. PubMed ID: 24747357
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Antiparkinsonian efficacy of a novel transdermal delivery system for (+)-PHNO in MPTP-treated squirrel monkeys.
    Rupniak NM; Tye SJ; Jennings CA; Loper AE; Bondi JV; Hichens M; Hand E; Iversen SD; Stahl SM
    Neurology; 1989 Mar; 39(3):329-35. PubMed ID: 2784549
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Glia conditioned medium offers protection against the toxicity induced by 6-OH-dopamine in vivo].
    Rojo A; Mena-Gómez MA; Blázquez A; Casarejos MJ; Fontán-Barreiro A; de Yébenes JG
    Rev Neurol; 2002 Jun 16-30; 34(12):1112-8. PubMed ID: 12134273
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.